Forte Biosciences, INC Schedule 13G passive stakes

Alger Associates, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 17.7% of Forte Biosciences, Inc.'s common stock as of December 31, 2024.

Tybourne Capital Management and its affiliates have filed an amended Schedule 13G, revealing a 9.99% beneficial ownership stake in Forte Biosciences, Inc. as of December 31, 2024.

OrbiMed Advisors LLC and OrbiMed Capital LLC have jointly filed a Schedule 13G, revealing an aggregate beneficial ownership of 9.4% in Forte Biosciences, Inc.'s common stock as of December 31, 2024.

Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has disclosed a 2.5% beneficial ownership stake in Forte Biosciences, Inc., as detailed in their latest Schedule 13G filing.

Multiple Biotechnology Value Funds and affiliated entities, including Mark N. Lampert, have disclosed beneficial ownership of up to 9.99% of Forte Biosciences, Inc.'s common stock as of December 31, 2024.

Investment firm Ikarian Capital, along with Neil Shahrestani, has reported a 9.5% beneficial ownership stake in Forte Biosciences, Inc., holding 609,225 shares as of December 31, 2024.

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed a 10.0% beneficial ownership stake in Forte Biosciences, Inc. as of December 31, 2024.

Boothbay Fund Management, LLC and its Managing Member, Ari Glass, have disclosed a 6% beneficial ownership stake in Forte Biosciences, Inc. common stock.

Farallon Capital and its affiliated entities have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 3.4% in Forte Biosciences, Inc. as of December 31, 2024.

Nemean Asset Management, LLC and Steven M. Oliveira have disclosed a 6.76% beneficial ownership stake in Forte Biosciences, Inc., totaling 432,276 shares of common stock.